Aging is a risk factor for Alzheimer’s disease (AD). There are changes of brain metabolism and biometal fluxes due to brain aging, which may play a role in pathogenesis of AD. Positron emission tomography (PET) is a versatile tool for tracking alteration of metabolism and biometal fluxes due to brain aging and AD. Age-dependent changes in cerebral glucose metabolism can be tracked with PET using 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG), a radiolabeled glucose analogue, as a radiotracer. Based on different patterns of altered cerebral glucose metabolism, 18F-FDG PET was clinically used for differential diagnosis of AD and Frontotemporal dementia (FTD). There are continued efforts to develop additional radiopharmaceuticals or radiotracers for assessment of age-dependent changes of various metabolic pathways and biometal fluxes due to brain aging and AD with PET. Elucidation of age-dependent changes of brain metabolism and altered biometal fluxes is not only significant for a better mechanistic understanding of brain aging and the pathophysiology of AD, but also significant for identification of new targets for the prevention, early diagnosis, and treatment of AD.
JackCR Jr, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
3.
MandelkowE (1999) Alzheimer’s disease. The tangled tale of tau. Nature402, 588–589.
4.
LehmannS, DelabyC, TouchonJ, HirtzC, GabelleA (2013) Biomarkers of Alzheimer’s disease: The present and the future. Rev Neurol (Paris)169, 719–723.
5.
KarlnoskiRA, RosenthalA, KobayashiD, PonsJ, AlamedJ, MercerM, LiQ, GordonMN, GottschallPE, MorganD (2009) Suppression of amyloid deposition leads to long-term reductions in Alzheimer’s pathologies in Tg2576 mice. J Neurosci29, 4964–4971.
6.
SchroederSK, Joly-AmadoA, GordonMN, MorganD (2016) Tau-directed immunotherapy: A promising strategy for treatingAlzheimer’s disease and other tauopathies. JNeuroimmune Pharmacol11, 9–25.
7.
CohenAD, KlunkWE (2014) Early detection of Alzheimer’s disease using PiB and FDG PET. Neurobiol Dis72, 117–122.
8.
KemppainenNM, AaltoS, WilsonIA, NågrenK, HelinS, BrückA, OikonenV, KailajärviM, ScheininM, ViitanenM, ParkkolaR, RinneJO (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology68, 1603–1606.
9.
ChoiSR, GoldingG, ZhuangZ, ZhangW, LimN, HeftiF, BenedumTE, KilbournMR, SkovronskyD, KungHF (2009) Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J Nucl Med50, 1887–1894.
10.
WongDF, RosenbergPB, ZhouY, KumarA, RaymontV, RavertHT, DannalsRF, NandiA, BrasićJR, YeW, HiltonJ, LyketsosC, KungHF, JoshiAD, SkovronskyDM, PontecorvoMJ (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med51, 913–920.
11.
ZwanMD, BouwmanFH, KonijnenbergE, vander Flier WM, LammertsmaAA, VerheyFR, AaltenP, vanBerckel BN, ScheltensP (2017) Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther9, 2–.
VillemagneVL, OngK, MulliganRS, HollG, PejoskaS, JonesG, O’KeefeG, AckermanU, Tochon-DanguyH, ChanJG, ReiningerCB, FelsL, PutzB, RohdeB, MastersCL, RoweCC (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med52, 1210–1217.
14.
SabriO, SabbaghMN, SeibylJ, BarthelH, AkatsuH, OuchiY, SendaK, MurayamaS, IshiiK, TakaoM, BeachTG, RoweCC, LeverenzJB, GhettiB, IronsideJW, CatafauAM, StephensAW, MuellerA, KoglinN, HoffmannA, RothK, ReiningerC, Schulz-SchaefferWJ, FlorbetabenPhase 3 Study Group (2015) Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study. Alzheimers Dement11, 964–974.
15.
WoodH (2013) Alzheimer disease: [11C]PBB3–a new PET ligand that identifies tau pathology in the brains of patients with AD. Nat Rev Neurol9, 599–.
16.
MaruyamaM, ShimadaH, SuharaT, ShinotohH, JiB, MaedaJ, ZhangM, TrojanowskiJQ, LeeVM, OnoM, MasamotoK, TakanoH, SaharaN, IwataN, OkamuraN, FurumotoS, KudoY, ChangQ, SaidoTC, TakashimaA, LewisJ, JangMK, AokiI, ItoH, HiguchiM (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron79, 1094–1108.
17.
OssenkoppeleR, TolboomN, Foster-DingleyJC, AdriaanseSF, BoellaardR, YaqubM, WindhorstAD, BarkhofF, LammertsmaAA, ScheltensP, vander Flier WM, vanBerckel BN (2012) Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging39, 990–1000.
18.
HaradaR, OkamuraN, FurumotoS, TagoT, MaruyamaM, HiguchiM, YoshikawaT, AraiH, IwataR, KudoY, YanaiK (2013) Comon of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging40, 125–132paris.
19.
OkamuraN, FurumotoS, HaradaR, TagoT, YoshikawaT, Fodero-TavolettiM, MulliganPS, VillemagneVL, AkatsuH, YamamotoT, AraiH, IwataR, YanaiK, KudoY (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med54, 1420–1427.
KumarA, MuzikO, ShandalV, ChuganiD, ChakrabortyP, ChuganiHT (2012) Evaluation of age-related changes in translocator protein(TSPO) in human brain using (11)C-[R]-PK11195 PET. JNeuroinflammation9, 232–.
26.
KreislWC, LyooCH, McGwierM, SnowJ, JenkoKJ, KimuraN, CoronaW, MorseCL, ZoghbiSS, PikeVW, McMahonFJ, TurnerRS, InnisRB, BiomarkersConsortium PET Radioligand Project Team (2013) In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain136, 2228–2238.
27.
KreislWC, LyooCH, LiowJS, WeiM, SnowJ, PageE, JenkoKJ, MorseCL, ZoghbiSS, PikeVW, TurnerRS, InnisRB (2016) (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging44, 53–61.
28.
IkawaM, LohithTG, ShresthaS, TeluS, ZoghbiSS, CastellanoS, TalianiS, DaSettimo F, FujitaM, PikeVW, InnisRB, BiomarkersConsortium Radioligand Project Team (2017) 11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain. J Nucl Med58, 320–325.
29.
SuridjanI, RusjanPM, VoineskosAN, SelvanathanT, SetiawanE, StrafellaAP, WilsonAA, MeyerJH, HouleS, MizrahiR (2014) Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [(18)F]-FEPPA. Neuroimage84, 868–875.
30.
VarroneA, OikonenV, ForsbergA, JoutsaJ, TakanoA, SolinO, Haaparanta-SolinM, NagS, NakaoR, Al-TawilN, WellsLA, RabinerEA, ValenciaR, Schultze-MosgauM, ThieleA, VollmerS, DyrksT, LehmannL, HeinrichT, HoffmannA, NordbergA, HalldinC, RinneJO (2015) Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [(18)F]FEMPA in Alzheimer’s disease patients and control subjects. Eur J Nucl Med Mol Imaging42, 438–446.
31.
HarmanD (2006) Alzheimer’s disease pathogenesis: Role of aging. Ann N Y Acad Sci1067, 454–460.
32.
Joly-AmadoA, SerraneauKS, BrownlowM, Marínde Evsikova C, SpeakmanJR, GordonMN, MorganD (2016) Metabolic changes over the course of aging in a mouse model of tau deposition. Neurobiol Aging44, 62–73.
33.
KakimotoA, ItoS, MinoshimaS. Okada H, OuchiY (2016) Age-related sex-specific changes in the brain metabolism and morphology. J Nucl Med57, 221–225.
MosconiL (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging32, 486–510.
SimpsonIA, ChunduKR, Davies-HillT, HonerWG, DaviesP (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol35, 546–551.
FriedlandRP, BudingerTF, KossE, OberBA (1985) Alzheimer’s disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett53, 235–240.
40.
MinoshimaS, GiordaniB, BerentS, FreyKA, FosterNL, KuhlDE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol42, 85–94.
41.
DrzezgaA, LautenschlagerN, SiebnerH, RiemenschneiderM, WillochF, MinoshimaS, SchwaigerM, KurzA (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: A PET follow-up study. Eur J Nucl Med Mol Imaging30, 1104–1113.
42.
MosconiL, BertiV, GlodzikL, PupiA, DeSanti S, deLeon MJ (2010) Pre-clinical detection of Alzheimer’s disease usingFDG-PET, with or without amyloid imaging. J AlzheimersDis20, 843–854.
43.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
44.
KangJ, RivestS (2012) Lipid metabolism and neuroinflammation in Alzheimer’s disease: A role for liver X receptors. Endocr Rev33, 715–746.
TravisJ (1993) New piece in Alzheimer’s puzzle. Science261, 828–829.
47.
KandimallaRJ, PrabhakarS, BinukumarBK, WaniWY, GuptaN, SharmaDR, SunkariaA, GroverVK, BhardwajN, JainK, GillKD (2011) Apo-Eɛ4 allele in conjunction with Aβ42 and tau in CSF: Biomarker for Alzheimer’s disease. Curr Alzheimer Res8, 187–196.
48.
WyssMT, WeberB, TreyerV, HeerS, PellerinL, MagistrettiPJ, BuckA (2009) Stimulation-induced increases of astrocytic oxidative metabolism in rats and humans investigated with 1-11C-acetate. J Cereb Blood Flow Metab29, 44–56.
49.
OkadaM, NakaoR, MomosakiS, YanamotoK, KikuchiT, OkamuraT, WakizakaH, HosoiR, ZhangMR, InoueO (2013) . Improvement of brain uptake for in vivo PET imaging of astrocytic oxidative metabolism using benzyl [1-(11)C]acetate. Appl Radiat Isot78, 102–107.
50.
CastellanoCA, NugentS, PaquetN, TremblayS, BoctiC, LacombeG, ImbeaultH, TurcotteÉ, FulopT, CunnaneSC (2015) Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer’s disease dementia. J Alzheimers Dis43, 1343–1353.
51.
Courchesne-LoyerA, CroteauE, CastellanoCA, St-PierreV, HennebelleM, CunnaneSC (2016) Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab–10.1177/0271678X16669366.
52.
SalmonE, GregoireMC, DelfioreG, LemaireC, DegueldreC, FranckG, ComarD (1996) Combined study of cerebral glucose metabolism and [11C]methionine accumulation in probable Alzheimer’s disease using positron emission tomography. J Cereb Blood Flow Metab16, 399–408.
BishuS, SchmidtKC, BurlinTV, ChanningMA, HorowitzL, HuangT, LiuZ, QinM, VuongBK, UntermanAJ, XiaZ, ZametkinA, HerscovitchP, QuezadoZ, SmithCB (2009) Propofol anesthesia does not alter regional rates of cerebral protein synthesis measured with L-[1-(11)C]leucine and PET in healthy male subjects. J Cereb Blood Flow Metab29, 1035–1047.
55.
JęśkoH, WilkaniecA, CieślikM, HilgierW, GąssowskaM, LukiwW, AdamczykA (2016) Altered arginine metabolism in cells transfected with human wild-type beta amyloid precursor protein (βAPP). Curr Alzheimer Res13, 1030–1039.
56.
MacreadieIG (2008) Copper transport and Alzheimer’s disease. Eur Biophys J37, 295–300.
TorresJB, AndreozziEM, DunnJT, SiddiqueM, SzandaI, HowlettDR, SunasseeK, BlowerPJ (2016) PET Imaging of copper trafficking in a mouse model of Alzheimer’s disease. J Nucl Med57, 109–114.
60.
LutsenkoS, BhattacharjeeA, HubbardAL (2010) Copper handling machinery of the brain. Metallomics2, 596–608.
61.
DaviesKM, HareDJ, CottamV, ChenN, HilgersL, HallidayG, MercerJF, DoubleKL (2013) Localization of copper and copper transporters in the human brain. Metallomics5, 43–51.
62.
PengF, LutsenkoS, SunX, MuzikO (2012) Positron emission tomography of copper metabolism in the Atp7b-/- knock-out mouse model of Wilson’s disease. Mol Imaging Biol14, 70–78.
63.
PengF, LutsenkoS, SunX, MuzikO (2012) Imaging copper metabolism imbalance in Atp7b (-/-) knockout mouse model of Wilson’s disease with PET-CT and orally administered 64CuCl2. Mol Imaging Biol14, 600–607.
64.
XieF, XiY, PascualJM, MuzikO, PengF (2017) Age-dependent changes of cerebral copper metabolism in Atp7b-/- knockout mouse model of Wilson’s disease by [64Cu]CuCl2-PET/CT. Metab Brain Dis32, 717–726.
65.
CapassoE, DurzuS, PirasS, ZandiehS, KnollP, HaugA, HackerM, MeledduC, MirzaeiS (2015) Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med29, 482–488.
66.
PanichelliP, VillanoC, CistaroA, BrunoA, BarbatoF, PiccardoA, DuattiA (2016) Imaging of brain tumors with copper-64 chloride: Early experience and results. Cancer Biother Radiopharm31, 159–167.
67.
PengF, LuX, JanisseJ, MuzikO, ShieldsAF (2006) PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med47, 1649–1652.
68.
PengF (2014) Positron emission tomography for measurement of copper fluxes in live organisms. Ann N Y Acad Sci1314, 24–31.
69.
Niccoli AsabellaA, CasciniGL, AltiniC, PaparellaD, NotaristefanoA, RubiniG (2014) The copper radioisotopes: A systematic review with special interest to 64Cu. Biomed Res Int2014, 786463.
70.
HuetingR (2014) Radiocopper for the imaging of copper metabolism. J Labelled Comp Radiopharm57, 231–238.
71.
WardRJ, ZuccaFA, DuynJH, CrichtonRR, ZeccaL (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol13, 1045–1060.
72.
AshkenaziR, Ben-ShacharD, YoudimMB (1982) Nutritional iron and dopamine binding sites in the rat brain. . Pharmacol Biochem Behav17, 43–47.
73.
WillmoreLJ, SypertGW, MunsonJV, HurdRW (1978) Chronic focal epileptiform discharges induced by injection of iron into rat and cat cortex. Science200, 1501–1503.
74.
BruehlmeierM, LeendersKL, VontobelP, CalonderC, AntoniniA, WeindlA (2000) Increased cerebral iron uptake in Wilson’s disease: A 52Fe-citrate PET study. J NucI Med41, 781–787.
75.
MarkesberyWR, EhmannWD, AlauddinM, HossainTI (1984) Brain trace element concentrations in aging. Neurobiol Aging5, 19–28.
76.
AntoniniA, WettsteinA, SchmidR, LeendersKL (1996) Brain [52Fe]-transferrin uptake in patients with Alzheimer’s disease and healthy subjects: a positron emission tomography (PET) study. In FiskumG, ed. Plenum Publishers, New York and London, pp. 305–308.
77.
LovellMA, RobertsonJD, TeesdaleWJ, CampbellJL, MarkesberyWR (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci158, 47–52.
78.
SandsteadHH, FredericksonCJ, PenlandJG (2000) History of zinc as related to brain function. J Nutr130, 496S–502S.
79.
GrotzN, FoxT, ConnollyE, ParkW, GuerinotML, EideD (1998) Identification of a family of zinc transporter genes from Arabidopsis that respond to zinc deficiency. Proc Natl Acad Sci U S A95, 7220–7224.
80.
AssafSY, ChungSH (1984) Release of endogenous Zn2+ from brain tissue during activity. Nature308, 734–736.
81.
DeGradoTR, KempBJ, PandeyMK, JiangH, GundersonTM, LinscheidLR, WoodwickAR, McConnellDM, FletcherJG, JohnsonGB, PetersenRC, KnopmanDS, LoweVJ (2016) First PET imaging studies with 63Zn-zinc citrate in healthy human participants and patients with Alzheimer disease. Mol Imaging15, 1–10.
82.
DeGradoTR, PandeyMK, ByrneJF, EngelbrechtHP, JiangH, PackardAB, ThomasKA, JacobsonMS, CurranGL, LoweVJ (2014) Preparation and preliminary evaluation of 63Zn-zinc citrate as a novel PET imaging biomarker for zinc. J Nucl Med55, 1348–1354.
83.
HareDJ, FauxNG, RobertsBR, VolitakisI, MartinsRN, BushAI (2016) Lead and manganese levels in serum and erythrocytes in Alzheimer’s disease and mild cognitive impairment: Results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Metallomics8, 628–632.
84.
WootenAL, AwedaTA, LewisBC, GrossRB, LapiSE (2017) Biodistribution and PET Imaging of pharmacokinetics of manganese in mice using Manganese-52. PLoS One12, e0174351.
